Pages that link to "Q33917786"

The following pages link to Effect of paricalcitol and cinacalcet on serum phosphate, FGF-23, and bone in rats with chronic kidney disease (Q33917786):

Displaying 42 items.

• Primary hyperparathyroidism in children and adolescents (Q26853701) (← links)
• Cardiovascular Risk Factors and Chronic Kidney Disease-FGF23: A Key Molecule in the Cardiovascular Disease (Q27024043) (← links)
• The use of fibroblast growth factor 23 testing in patients with kidney disease (Q33835743) (← links)
• 1,25(OH)2D3 alters growth plate maturation and bone architecture in young rats with normal renal function (Q33939559) (← links)
• FGF23 induces left ventricular hypertrophy (Q34028891) (← links)
• The calcium-sensing receptor complements parathyroid hormone-induced bone turnover in discrete skeletal compartments in mice (Q34139850) (← links)
• Velcalcetide (AMG 416), a novel peptide agonist of the calcium-sensing receptor, reduces serum parathyroid hormone and FGF23 levels in healthy male subjects (Q34385273) (← links)
• Tertiary excess of fibroblast growth factor 23 and hypophosphatemia following kidney transplantation (Q34500628) (← links)
• Long-term clinical practice experience with cinacalcet for treatment of hypercalcemic hyperparathyroidism after kidney transplantation (Q35226929) (← links)
• Effect of Cinacalcet and Vitamin D Analogs on Fibroblast Growth Factor-23 during the Treatment of Secondary Hyperparathyroidism (Q35682152) (← links)
• Vitamin D therapy in chronic kidney disease and end stage renal disease (Q35758581) (← links)
• Update on fibroblast growth factor 23 in chronic kidney disease (Q36210285) (← links)
• The consequences of chronic kidney disease on bone metabolism and growth in children (Q36318290) (← links)
• Paricalcitol does not improve glucose metabolism in patients with stage 3-4 chronic kidney disease (Q36431285) (← links)
• Vitamin D receptor agonists increase klotho and osteopontin while decreasing aortic calcification in mice with chronic kidney disease fed a high phosphate diet (Q36438261) (← links)
• Calcitriol Suppression of Parathyroid Hormone Fails to Improve Skeletal Properties in an Animal Model of Chronic Kidney Disease (Q36666085) (← links)
• Phosphate Toxicity in CKD: The Killer among Us (Q36965142) (← links)
• Fibroblast growth factor-23: what we know, what we don't know, and what we need to know (Q37162723) (← links)
• Mechanistic analysis for time-dependent effects of cinacalcet on serum calcium, phosphorus, and parathyroid hormone levels in 5/6 nephrectomized rats (Q37328071) (← links)
• Calcium regulates FGF-23 expression in bone (Q37331084) (← links)
• Phosphate: an old bone molecule but new cardiovascular risk factor (Q37492019) (← links)
• Clinical practice. Fibroblast growth factor (FGF)23: a new hormone (Q37824821) (← links)
• Does it matter how parathyroid hormone levels are suppressed in secondary hyperparathyroidism? (Q37891153) (← links)
• Mineral and bone disorders in children with chronic kidney disease (Q37938689) (← links)
• Vitamin D receptor activation and cardiovascular disease (Q38069143) (← links)
• The calcium-sensing receptor in bone--mechanistic and therapeutic insights (Q38370639) (← links)
• Pathophysiology of Calcium, Phosphorus, and Magnesium Dysregulation in Chronic Kidney Disease. (Q38572880) (← links)
• FGF23 from bench to bedside. (Q38728860) (← links)
• Vitamin D in patients with chronic kidney disease: a position statement of the Working Group "Trace Elements and Mineral Metabolism" of the Italian Society of Nephrology (Q38803449) (← links)
• Cinacalcet (Sensipar) provides no measurable clinical benefits for patients with primary hyperparathyroidism and may accelerate bone loss with prolonged use. (Q39259222) (← links)
• Comparison of active vitamin D compounds and a calcimimetic in mineral homeostasis (Q41575719) (← links)
• Which vitamin D in CKD-MBD? The time of burning questions (Q42562972) (← links)
• Calcimimetics and outcomes in CKD. (Q42727545) (← links)
• Cinacalcet treatment decreases plasma fibroblast growth factor 23 concentration in haemodialysed patients with chronic kidney disease and secondary hyperparathyroidism (Q46921995) (← links)
• Approach to cardiovascular disease prevention in patients with chronic kidney disease (Q49136022) (← links)
• Impact of long-term cinacalcet, ibandronate or teriparatide therapy on bone mineral density of hemodialysis patients: a pilot study (Q51191871) (← links)
• The role of fibroblast growth factor-23 in cardiorenal syndrome. (Q53989980) (← links)
• Cinacalcet treatment and serum FGF23 levels in haemodialysis patients with secondary hyperparathyroidism (Q57218945) (← links)
• Cinacalcet lowers FGF-23 level together with bone metabolism in hemodialyzed patients with secondary hyperparathyroidism (Q84847501) (← links)
• [FGF23 and the heart] (Q86277253) (← links)
• Changes in bone mineral metabolism parameters, including FGF23, after discontinuing cinacalcet at kidney transplantation (Q87653257) (← links)
• Vitamin D and Calcimimetics in Cardiovascular Disease (Q88648846) (← links)